Adoptive Cell Therapy and Engineered T-cell Research
USWM Ct LLC supports clinical research centered on autologous T-cell therapies and genetically modified cellular products for solid tumors. Its trial portfolio includes studies of NY-ESO-1 and LAGE-1a targeted cell therapies, with attention to tumors expressing these cancer-testis antigens.
- Autologous genetically modified T cells
- NY-ESO-1 and LAGE-1a positive solid tumors
- Long-term follow-up after cell therapy
The sponsor’s research activity also includes monitoring of delayed adverse events associated with genetically modified cell products.
Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
A major therapeutic focus is advanced synovial sarcoma and myxoid/round cell liposarcoma (MRCLS), especially in HLA-A*02 positive subjects with MAGE-A4 expressing disease. Trial activity in this area reflects an interest in rare soft tissue sarcomas with defined antigen expression.
- Advanced synovial sarcoma
- Myxoid/round cell liposarcoma (MRCLS)
- MAGE-A4 expressing tumors
These studies place emphasis on tumor-specific immunotherapy for sarcoma subtypes with limited treatment options.
Recurrent Ovarian Cancer and Gynecologic Oncology
The sponsor funds research in recurrent ovarian cancer, including MAGE-A4 positive disease in HLA-A2 selected participants. This area extends into broader gynecologic oncology, with relevance to ovarian carcinoma and related solid tumors.
- Recurrent ovarian cancer
- MAGE-A4 positive disease
- HLA-A2 selected subjects
Clinical interest also aligns with combination treatment approaches involving immune checkpoint inhibition.
Advanced Solid Tumors in Oncology
USWM Ct LLC’s portfolio includes broader studies in advanced cancers and solid tumors, with disease coverage spanning non-small cell lung cancer (NSCLC), urothelial cancer, esophageal cancer, gastric cancer, head and neck cancer, melanoma, and endometrial carcinoma.
- Non-small cell lung cancer (NSCLC)
- Urothelial cancer
- Melanoma
These programs indicate sustained involvement in solid tumor immunotherapy across multiple advanced malignancies.
